Table 1.
HDACs indicates histone deacetylases; mTOR, mammalian target of rapamycin.
| Agent | Target | Route | Phase | N | PR | CR | PR + CR | 1st author |
|---|---|---|---|---|---|---|---|---|
| MDX060 [7] | CD30 | IV | II | 47 | 2 | 2 | 4 (8%) | Ansell |
| SGN30 [8] | CD30 | IV | II | 38 | 0 | 0 | 0 (0%) | Forrero-Torres |
| SGN35 [10] | CD30 | IV | I | 45 | 10 | 7 | 17 (37%) | Younes |
| SGN35 [11] | CD30 | IV | I | 31 | 6 | 10 | 16 (46%) | Fanale |
| Panobinostat [25] | HDACs | Oral | II | 13 | 7 | 0 | 7 (58%) | Dickinson |
| Panobinostat [26] | HDACs | Oral | II | 129 | 29 | 4 | 33 (26%) | Sureda |
| MGCD0103 [30] | HDACs | Oral | II | 21 | 6 | 2 | 8 (38%) | Bociek |
| Vorinostat [31] | HDACs | Oral | II | 25 | 1 | 0 | 1 (4%) | Kirshbaum |
| Everolimus [45] | mTOR | Oral | II | 19 | 8 | 1 | 9 (47%) | Johnston |
| Lenalidomide [47] | ? | Oral | II | 35 | 5 | 1 | 6 (17%) | Fehniger |
| Lenalidomide [48] | ? | Oral | II | 15 | 2 | 0 | 2 (13%) | Kuruvilla |